Preclinical Studies on Metal Based Anticancer Drugs as Enabled by Integrated Metallomics and Metabolomics

Galvez, L.; Rusz, M.; Schwaiger-Haber, M.; et al.

Oxaliplatin is a chemotherapy drug administered to aid treatment of metastatic colorectal cancer. Despite its regularity, the impact of this metallodrug on drug uptake/distribution and the metabolome remains unclear. In an effort to address this, Koellensperger and colleagues developed an integrated metallomics/metabolomics method for evaluating sensitive/resistant human colon cancer cell models. This approach involved adding a U-¹³C metabolite yeast extract (ISO1) at the extraction stage for normalization and improved repeatability, with split analysis for platinum (by ICP-MS) and metabolite (by HILIC-MS/MS) measurement. The combined results shed light on oxaliplatin resistance mechanisms, with future studies needed to investigate the effects of inhibiting fatty acid oxidation on drug sensitivity/resistance.